Table 1.
Summary of key components of each strategy.
Fig 1.
Model diagram of strategies for P. vivax treatment in males.
Fig 2.
Model diagram of strategies for P. vivax treatment in females.
Table 2.
All costs are listed in 2014 United States Dollars.
Table 3.
Costs and disability adjusted life year (DALY) results over one year per primary episode treated in the base case analysis and probabilistic sensitivity analysis (PSA).
All costs are in 2014 United States Dollars.
Table 4.
The table shows simulated outcomes for 1000 P. vivax malaria patients of undetermined G6PD status at attendance, if they were managed according to each of three strategies (chloroquine, primaquine and screening) according to G6PD status, treatment given and the test result if screened.
Fig 3.
One-way sensitivity analysis results on costs and disability-adjusted life-years (DALYs) for the comparison of the screening strategy with the chloroquine strategy in males.
The ranges used are specified in Table 2. See S3 Appendix for all one-way sensitivity analysis results.
Fig 4.
Cost-effectiveness plane showing the incremental costs and DALYs averted from the probabilistic sensitivity analysis.
Results show the screening strategy versus: A) the chloroquine strategy in males, B) the primaquine strategy for males, C) the chloroquine strategy in females and D) the primaquine strategy in females.
Fig 5.
Cost-effectiveness acceptability curves.
Results show the screening strategy versus: A) the chloroquine strategy in males, B) the primaquine strategy for males, C) the chloroquine strategy in females and D) the primaquine strategy in females.
Fig 6.
Two-way sensitivity analysis results showing the impact of changes in the level of adherence to primaquine regimens.
Green represents disability-adjusted life-years (DALYs) averted by the screening strategy for a cohort of 1000 individuals. For costs, yellow indicates increased costs and blue indicates cost savings for the screening strategy for one individual. For net monetary benefit (NMB), purple indicates scenarios where the screening strategy would be cost-effective at a threshold of US$500 (T) where NMB = T × ΔDALYs– ΔCosts.